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CHAPTER 1: Introduction
An application of mathematical modeling to multiple drug cancer treatments is con-
sidered. The purpose of such research is to obtain a sufficiently faithful model so that
parameters are measurable and meaningful. This can eventually lead to decision making
that is based on quantitative feedback from patient data. The purpose of this paper is to
use stochastic models to analyze the impact of different drug treatments on cancer and to
model drug resistance by cancer cells. The mathematical models compare current single
cancer treatments results with combinations of multiple drug treatment results. Using var-
ious parameters for the model, the probability of treatment success is calculated. Finding
and utilizing different strategies for cancer treatment will improve the chances of treatment
success.
There are four main stages of cancer: initiation stage, promoted stage, tumor growth
stage, and metastatic stage. Exposure to external substances, as well as the body’s natural
aging process, can increase the progression of these stages. Chemotherapy is the use of
various drugs to slow and/or halt the cancer’s development. This study looks at a two-
drug cocktail as a treatment strategy and uses both deterministic and stochastic models to
analyze the outcomes using EXCEL programs.
Deterministic equations lead to no probability of cure, which is not realistic. On
the other hand, the stochastic model actually models the probability of a cure. Stochastic
processes are non-deterministic and show a random variable’s progression over time. A
stochastic process allows a model for estimating the probability of success.
CHAPTER 2: Basic Biological Concepts and Definitions
The progress of cancer involves four main stages. Initiation involves changes to the
genotype of the cell. To become fully cancerous, a cell must be promoted. Tumor growth
is the result of the excretion of mitogens called vascular endothelial growth factor, VEGF,
which stimulate the growth of vascular pathways to the cancer cells. At the last stage, can-
cer becomes metastatic, which results in the flow of cells into the blood stream. Exposure
to radiation, toxins, viruses, or high concentrations of non-toxic substances can increase
the speed of these stages. Natural aging can also lead to changes of states. The protein p53
is responsible for suppressing cell changes, also called the “guardian of the genome”. Its
inability to function properly has been connected to the progress of disease. Conversely,
excessively high levels of p53 can result in accelerated aging. See [7], [2], [8], [6], [5].
Various drugs are used to treat cancer and halt cellular advancement to the next stage.
This can be done in a series of drug treatments, or all at once in the form of a drug cocktail.
A shortcoming with the series approach is that there are cells that are resistant to any single
drug, and a portion of these will survive and thrive after the first treatment. This opens the
opportunity for the disease to progress before the next drug treatment.
The cocktail approach creates an environment whereby a cancer cell must traverse
one of several pathways in order to survive the treatment. In this study, cancer cells may
die but are assumed not to reproduce during the treatment period.
The various growth and transfer parameters will have one pre-treatment value before
the treatment and then their treatment value. During this study, the pre-treatment values
will be assumed to be smaller than the treatment values and set to zero. Cells that are
not significantly affected by the use of one or more drugs are known as resistant cells. In
combination therapy or polytherapy, the probability of a cancer cell becoming resistant is
independent of the turnover rate. The turnover rate is the ratio of natural cell death to the
3replication rate of a cancer cell in lack of a treatment. The generation of resistance-mutated
cells in the pre-treatment phase strongly depends on the turnover rate when two or more
drugs are used. There is also the phenomenon of a cancer cell becoming resistant to the
drugs before they are used. This is known as a pre-existence. The pre-existence of resistant
cells plays an important role on the effectiveness of the treatment in a real clinical setting.
2.1 States and Their Connection with Decay and Mutation Rate Constants
In this thesis, we will closely follow the approach of [7], although the emphasis will be
on solving systems of differential eqations. Parameters are denoted in various ways with
κ∗, τ∗ depending on the processes involved. The decay-rate constants are the rate of cell
death due to the treatment and is denoted κ. The states that a single cell can be in are
denoted by a vector ~s ∈ Zm2 when m drugs are used, and Z2 = {0,1} represents the two
conditions of being susceptible, 0 or resistant, 1. Two important states will reappear in our
discussion, the fully susceptible (zero) state and the fully resistant (one) state
~0 = 〈0,0, . . . ,0〉 , ~1 = 〈1,1, . . . ,1〉 ,
respectively. We assume,
κ~s > 0 ∀~s ∈ (Z2)m−{~1} , κ~1 = 0 .
What this represents is that every state has the possibility of resulting in the death of cancer
cells, except the ~1 state, where the cell is fully resistant to all the drugs in the cocktail.
The state vector ~s will change abruptly over time (ie. changes are discrete). What can be
modeled continuously are the probabilities of being in a state. The number of drugs that a
cell is resistant to, at some point in the treatment, is
4• number of drug resistances: #(~s) = ~1 ·~s = ∑mi=1 si ,
which gives for the two special cases,
• susceptible to all drugs in the cocktail: #(~0) = 0
• fully resistant to the treatment: #(~1) = m.
The mutation or transition-rate constants are denoted by τ. In specific situations,
we use the expression τ ba to denote the rate of transition from state b to state a. These
are characteristics of the relevant drug but also of the type of cancer to which it is being
applied. There are important features of the treatment process that we note.
• a cell never transitions back to itself: τ aa = 0 ,
• the treatment cannot make resistant cells susceptible: τ ba > 0 =⇒ τ ab = 0 .
As the cells reside in an environment of a drug cocktail, two changes can occur: either the
cell dies (with probability proportional to κ), or the cell transforms (with probability pro-
portional to τ). We assume that a transformation occurs from at least a partially susceptible
cell, to a cell that is resistant to only one more drug.
Figure 1: Example path of cells through a 4 drug-cocktail therapy.
The biological aspects that determine the processes of death or mutation are very com-
plex, so they are best dealt with using a statistical approach.
CHAPTER 3: Basic Statistical Concepts and Definitions
In most of this thesis, a basic two-state system is considered. When there are many cells
involved, then we work with a string of such states.
Definition 1. A binary (base 2) integer is a finite string of 0’s and 1’s that can be represented
as a vector~s ∈ (Z2 = {0,1})m so that the equivalent decimal (base 10) expression is
binary→ ~s = 〈s1, s2, . . . sm〉 ≡
m−1
∑
i=0
si+1 ·2m−i−1 ← decimal .
Remark 3.1. Example numbers are 0≡ 00, 01≡ 1, 10≡ 2 and 11≡ 3.
To incorporate uncertainty in our study, there is a need for appropriate terminology.
Definition 2. The sample space used here is defined to be
Ω = (Z2)m ≡ {~s = 〈s1, s2, . . . , sm〉 | si ∈ Z2 = {0,1} ∀i ∈ {1,2, . . .m}} .
Since Ω is finite, the set of possible events is the power set
Pm2 ≡ 2Ω = {{~s1, . . .~si, . . . ,~sk} |~si ∈Ω, 0≤ k ≤ m} .
Given a probability measure P : Pm2 → [0,1], where
P( /0) = 0, P(Ω) = 1, P(A∪B) = P(A)+P(B)−P(A∩B),
Then the triple 〈Ω,Pm2 ,P〉 is a probability space.
Next, to model the random nature of the process, we recall the following:
Definition 3. A Markov process is a stochastic process with the following properties:
6• the number of possible outcomes or states is finite,
• the outcome at any stage depends only on the outcome of the previous stage,
• the probabilities are constant over time.
These ideas can be extended to a continuous Markov process or chain.
The process we consider takes place in a combinatorial mutation network, as described
in [7]. In a small time period ∆t > 0, a cancer cell can either (i) remain in its present state,
(ii) die due to one of the drugs, or (iii) transform (mutate) into a form that is resistant to
one of the drugs in the cocktail. The probability of this occurring is proportional to ∆t, but
is considered independent of t itself. We ignore the possibility of a cell becoming resistant
to two drugs at the same time, or at least within an interval of size ∆t.
3.1 Time-varying Probabilities
As the problems considered become more complex, the description for the state space Ω
must be expanded. Consider the finite sequence 〈ιk〉Nk=1 where ιk ∈ N0 are the numbers of
susceptible and the number of resistant cancer cells in the system of N cells, at some point
in time,
Ω ≡ { 〈ι0, ι1 . . . ιN〉 | ιk ∈ N0 } .
Susceptible cells have a high likelihood of being killed-off by the use of a drug. Thus, such
cells are susceptible to the treatment.
Resistant cells are not significantly affected by the use of one or more drugs. Such cells
may survive the entire treatment consisting of a cocktail of drugs.
Let pi~s(t, ι~s) denote the probability ι~s ∈N0 of cells of phenotype~s that are present in the
system at time t. For two drugs, the process is modeled as a random walk in 4-dimensional
space.
7Dummy variables x∗ ∈ R will be used in the study of this system. In the case of a
single-cell system, x0 corresponds to susceptible cells, and x1 corresponds to resistant cells.
In a two-cell system, there are 4 dummy variables, x00, x10, x01 and x11 with obvious
representation. In the case of m ∈ N drugs, we need the notation
xs1 s2 ...sm ∈ R .
The use of m is to indicate that this is the number of mutations required for the cell to
become resistant to the cocktail of m drugs. There are
n ≡ 2m different phenotypes ,
where~0 corresponds to susceptible to all drugs, and~1 corresponds to resistant to all drugs.
Furthermore, there are
(
m
k
)
different phenotypes resistant to exactly k of the drugs ,
for 0≤ k≤m. Our goal is to study the probability generating function PGF, Ψ, associated
with the treatment process. The PGF is similar to the moment generating function, MGF
used in the study of continuous state spaces. However, since the state space Ω is discrete,
we introduce variables x∗ ∈ R, and write
Ψ(t; x~s) = ∑
ι~s
pi~s (t; ι~s) ·∏
k
x
ι~sk
k . (3.1)
This is a multi-variable function, and there are several special cases where information can
8be easily deduced, once it is constructed. For instance,
Ψ(t;~1) = ∑
ι~s
pi~s (t; ι~s) = 1 ,
as must be the case for probabilities.
3.2 Probability Generating Functions
A generating function for a discrete random variable S, that has possible values sn ∈ R
for n ∈ N, is a series expressed in term of a dummy variable, t. A probability generating
function PGF, can only be used with discrete integral distributions. The most common
distributions are the binomial, the Poisson, and the geometric. See [11]. The random
variable S in the distribution can take only non-negative integer values. The PGF is defined
by
Ψs(t) ≡
∞
∑
n=0
P(S = sn) tn , (3.2)
where P(S = s) is the probability of S taking on the value s. A simple example of a PGF is
as follows: let the random variable S be defined by
S =

1 if the outcome is a success ,
0 if the outcome ends in a failure .
.
The PGF can be expressed in terms of moments, which leads to another type of gen-
erating function called a moment generating function, MGF. MGFs can be used with both
discrete and continuous distributions, and are therefore less restrictive than PGFs. See [11].
9MGFs are defined for a random variable X , in terms of a real number t, by
Mx(t) = E[etx] =

∑etx f (x) if X is discrete ,∫ ∞
−∞ etx f (x)dx if X is continuous .
. (3.3)
While moment generating functions are very useful, probability generating functions are
used in this study. Here the two states for S are:
success = susceptible , failure = resistant.
3.2.1 Two Coin-Toss Model
Consider the example of tossing two coins where the possible outcomes are
s ∈ {HH, T H, HT, T T} ≡ {0, 1, 2} ,
but the order is unimportant. Letting H ≡ 0 and T ≡ 1 we obtain the PGF
Ψany order(x) = ∑pis∏xs = 0.25 + 0.5x + 0.25x2 = (1+ x)2/4 ,
for x ∈ [0,1]. This leads to two identities
Ψ(0) = P(No “T ”) = 0.25 , Ψ(1) = 1 .
However, there are more identities involving the derivatives of the PGF:
Ψ′(1) = Mean = 1 , Ψ′′(1)+Ψ′(1)− (Ψ′(1))2 = Var = 0.5 .
Conversely, suppose order is important in the two-coin toss experiment. Then the pos-
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sible outcomes are
s ∈ {HH, T H, HT, T T} ≡ {00, 01, 10, 11} ,
Then the associated PGF is
Ψorder important(x,y) = 0.25 + 0.25x + 0.25y + 0.25xy = (1+ x)(1+ y)/4 ,
which gives the obvious identities
Ψ(0,0) = P(No“T ”) = 0.25 , Ψ(1,1) = 1 ,
but also identities involving partial derivatives:
∂xΨ(1,1) = P(y = H|x = H) = 0.5 .
3.3 Kolmogorov Forward Equation
A discrete stochastic process {Sn}n∈Z, where the Sn take their values in a sample space
S , is Markovian if the statistics of Sn depend only on the value of Sn−1. For any r ∈ R, this
can be expressed as
P(Sn ≤ r | sn−1,sn−2, . . .) = P(Sn ≤ r | sn−1) .
Now, if we had all information on these conditional probabilities, then we could compute
the probability
P(Sn ≤ r) = ∑
sn−1∈S
P(Sn ≤ r | sn−1)P(sn−1) .
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These are the Chapman-Kolmogorov equations. For our application, these equations were
used for computing nth-step transition probabilities Pni j from a state i to a state j. In this
setting, the equations take the form
Pn+mi j =
∞
∑
k=0
Pnik P
m
k j , for all n,m> 0, ∀i, j ∈ N0 . (3.4)
The Kolmogorov Forward Equation and Backward Equation are derived from (3.4)
by allowing n and m to be continuous variables. In particular, let m = ∆t > 0 be a small
real number. Then subtracting Pni j from both sides gives
Pn+∆ti j −Pni j =
∞
∑
k=0
Pnik
(
P∆tk j − P0k j
)
, (3.5)
where P0kk = 1 but P
0
k j = 0 for k 6= j. See [12]. (Note, this condition is also written as
P0k j = δ
j
k where δ
j
k is the Kronecker delta so that δ
k
k = 1 and vanishes otherwise.) Dividing
both sides by ∆t > 0 and taking the limit as ∆t → 0, equation (3.5) becomes a differential
equation. Let n = t ∈ R+0 . Then we have the system of ordinary differential equations,
ODEs, for the Pi j(t) functions,
P ′i j(t) =
∞
∑
k=0
Pik(t) P′k j(0) , (3.6)
for t ≥ 0. Now, we see that the rates of change depend on information only at t = 0, so they
are time-independent. Thus (3.6) is a constant-coefficient ODE where we denote
κi = −P ′ii(0) ≥ 0 and τ kj = P ′k j(0) .
This gives the Kolmogorov Forward Equations KFE in the form
P ′ii(t) = ∑
k 6=i
τki Pik(t) − κi Pii(t) (3.7)
12
P ′i j(t) = ∑
k 6=i, j
τkj Pik(t) − κ j Pi j(t) + τ ij Pii(t) . (3.8)
In physical applications this is sometimes called the Fokker-Planck Equation and in
biology it is called the Chemical Master Equation. We use the KFE later in the study when
working with stochastic differential equations.
3.4 Stochastic Differential Equations
To understand data that is generated from a random process, one needs to have probabil-
ity distributions pi∗ that model the output. When the distributions pi∗(t) change over time
they satisfy a KFE written in generality as
dpiI
dt
= ∑
I−
KI− · I− ·piI− + KI0 · I ·piI + ∑
I+
KI+ · I+ ·piI+ , (3.9)
for coefficients K∗ that depend on the process. Here I− corresponds to preceding states, and
I+ forthcoming states. Also, K0 ≤ 0 is required for stability.
For the KFE in (3.9) a dummy variable x ∈ [0,1] is introduced. A probability density
function, PDF, is constructed from equation (5.10),
Ψ(t;x) ≡ ∑
I
piI(t) ·∏xI . (3.10)
To determine expectations, one can apply a partial differential operator PDO, to the
PDF. For example (
xI∗∂xI∗Ψ
)
(t;~1) = 〈I∗〉t ,
is the time-varying expectation of the s∗ random variable. Taking the time derivative of
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(3.10) and using equation (3.9) gives a system of partial differential equations, PDEs,
∂Ψ
∂t
= ~v ·∇Ψ , (3.11)
where the components~v∗ are quadratic polynomials in x. Since this equation is hyperbolic
and first order, one can use the method of characteristics to write a system of ODEs to solve
the PDEs.
CHAPTER 4: Strategies of Numerical Analysis
4.1 Ordinary Differential Equations
Consider a differentiable t-varying vector of variables ~x(t) with values in Rn. The rate
of change vector ~F may depend on t explicitly, and it may depend on ~x, which is an im-
plicit dependence on t (the only independent variable). A system of ordinary differential
equations, ODEs, is given by
d~x
dt
≡ ~x ′(t) = ~F (t;~x(t)) ≡ ~F (t;~x) . (4.1)
When ~F does not depend on t explicitly, then equation (4.1) is called autonomous expressed
as ~F = ~F(~x). When ~F(t;~x) = M(t)~x for some n× n matrix M with continuously varying
components, then equation (4.1) is called linear.
This thesis will work with constant n×n matrices M in which case equation (4.1) is an
n-dimensional constant coefficient system of ODEs. Given initial conditions~x0 ∈ Rn there
is a unique solution~x(t), at least on some interval [0,T ]. In particular,
d~x
dt
= M~x and ~x(0) = ~x0 =⇒ ~x(t) = exp [M t]~x0 . (4.2)
Using a Taylor expansion, the solution can be written as
~x(t) = eMt~x0 =
∞
∑
k=0
tk
k!
Mk ·~x0 = ~x0 + tM~x0 + (t2/2)M2~x0 + O(t3) . (4.3)
We do not focus on the variety of solutions that one obtains. See [1]. However, the matrices
considered here do have the special property that the sum of their columns equals 0. This
encodes the conservation of probabilities when applied to Markov processes.
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4.2 First-Order Partial Differential Equations
An equation that relates an unknown function of two or more independent variables
to its partial derivatives is called a partial differential equation, PDE. The study of such
equations is a continuing area of research. Non-linear PDEs are particularly difficult to
solve.
We start with the simple case of a general first-order linear, non-homogeneous PDE,
which takes the form,
A(x,y)
∂u
∂x
+ B(x,y)
∂u
∂y
+ C(x,y)u = R(x,y) . (4.4)
If A(x,y) or B(x,y) are equal to zero then the PDE can be reduced to a first order ODE.
See [11].Otherwise, one can use the method of characteristics to reduce (4.4) to a system
of ODEs. See [3]. This works by artificially introducing a variable t and assuming that
u(x,y) = u(x(t),y(t)). Then, taking the full derivative in t gives
du
dt
=
dx
dt
ux +
dy
dt
uy . (4.5)
Now, comparing (4.4) and (4.5) gives the system of ODEs
dx
dt
= A(x,y) ,
dy
dt
= B(x,y) ,
du
dt
= R(x,y) − C(x,y)u . (4.6)
The price that one pays for this conversion to (4.6) is that the linear PDE in (4.4) is now a
system of non-linear (in general) ODEs.
Example 4.1. Consider the linear non-homogeneous PDE
yux + 6uy = x + y , u(x,0) = x+2 . (4.7)
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The method of characteristics gives the system of ODEs
dx
dt
= y ,
dy
dt
= 6 ,
du
dt
= x + y . (4.8)
It is best to start with the middle equation, which gives
y(t) = 6t + y0 ,
where y0 ∈ R is an arbitrary constant. However, if the characteristic line y = 0 is forced to
correspond to t = 0, then y0 = 0,in which case y(t) = 6t. This is substituted into the first
equation to give
x(t) = 3t2 + x0 ,
and since x varies along the characteristic, we allow x0 ∈ R. This can now be inserted into
the third equation to give
u′ = 3t2 + x0 + 6t =⇒ du = (3t2+6t+ x0)dt =⇒ u(t) = t3+3t2+ x0t+C .
The choice of the arbitrary constant C will help to understand the solution. In particular,
let C = u0. Then, using the Cauchy data: u(x,0) = x+ 2, immediately gives u0 = x0 +
2.Combining u(t) and x(t) gives
u(t) = t3 + 3t2 + x0 t + x0 + 2
= −2t3 + (3t2+ x0)t + (3t2+ x0) + 2 .
Now, using t = y/6 and x = 3t2+ x0, we obtain
u(x,y) = −2(y/6)3 + xy/6 + x + 2 .
It is easy to check that u(x,y) solves equation (4.7).
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Linear PDEs are not so easy to solve in general and sometimes we need to solve the
system of ODEs in (4.8) in order to solve the corresponding PDE. A simplification occurs
for homogeneous PDEs.
Example 4.2. Consider the linear homogeneous PDE
yux + 6uy = 0 , u(x,0) = x+2 . (4.9)
Again, the method of characteristics gives the simple system of ODEs
dx
dt
= y ,
dy
dt
= 6 ,
du
dt
= 0 . (4.10)
The middle equation gives y(t) = 6t, the first equation gives x(t) = 3t2 + x0, and the last
equation simply gives u(t) = u0. The Cauchy data implies u(x,0) = x+2, or simply u0 =
x0+2. Combining u(t) and x(t) gives
u(t) = u0
= x0 + 2
= x − 3t2 + 2 ,
which, upon elimination of t using t = y/6, gives
u(x,y) = x − y2/12 + 2 .
This solves equation (4.9). However, along the parameterized characteristic curve
γ(x0,0)(t) = (x(t), y(t)) =
(
3t2+ x0, 6t
)
, t ∈ R or simply: x = y2/12 + x0 ,
the solution u(x,y) is a constant, with value
u|γ(x0,0) = u0 = x0+2 .
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Thus the characteristic curves γ(x0,0) contain a lot of information about the PDE (4.9).
Comparing the two examples, we see that homogeneous PDEs have special properties
that are contained in their associated characteristic curves (or simply characteristics).
Example 4.3. Finally, consider the hyperbolic PDE for solution u in terms of independent
variables t, x and y, where
yux + 6uy = ut , u(0,x,y) = x+ y+2 . (4.11)
Here the method of characteristics is more complicated, since now we must assume that
along a curve
γ(0,x0,y0)(t) = (t, x(t), y(t)) ,
that u can be computed, so that
du|γ
dt
=
∂u
∂t
+
dx
dt
∂u
∂x
+
dy
dt
∂u
∂y
=⇒ 0 = ut − yux − 6uy .
giving the equations for γ to be
dx
dt
∣∣∣∣
γ
= −y , dy
dt
∣∣∣∣
γ
= −6 , du
dt
∣∣∣∣
γ
= 0 , (4.12)
due to (4.11). The middle equation gives y(t) = −6t + y0 and the first equation gives
x(t) = 3t2− y0t+ x0. The last equation in (4.12) gives u(t) = x0+ y0+2 using the Cauchy
data in (4.11)in the form u(0,x0,y0) = x0+ y0+2. Combining u(t) and x(t) gives
u(t,x,y) = x0 + y0 + 2
=
(
x − 3t2 + (y+6t) t) + (y + 6t) + 2
= x + (t+1)y + 3t2 + 6t + 2 ,
which solves the PDE in (4.11). The parameterized characteristic curve, along which u
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is the constant u0 = x0+ y0+2, is given by
γ(0,x0,y0)(t) = (t,x(t), y(t)) =
(
t, 3t2− y0 t+ x0,−6t+ y0
)
, t ∈ R .
Knowledge of γ provides a way to understand the solution u.
It will be seen that the PDF is constant along characteristics, and thus the asymptotes
of the probability distributions can be determined with relative ease.
4.3 Euler’s Method for solving ODEs
Euler’s method is used to solve differential equations by considering an associated dif-
ference scheme whose limit for small changes gives differentiation. It is only a first-order
method with regards to errors, and so Euler’s Method is often considered to be too unsta-
ble for practical applications. However, the equations considered here are linear and the
solutions are bounded. Thus, for the most part, Euler’s method is used within an EXCEL
spreadsheet program.
Suppose that ~F : N n+1ε → Rn is continuous in all variables in an ε-neighborhood of
(0,~x0), denoted
N n+1ε ≡ (−ε,ε)×M nε ⊂ Rn+1 where M nε ≡
(
~x0+(−ε,ε)~1
)
,
for some ε > 0. Furthermore, suppose that for each fixed t0, within ε of 0, the function
~F(t0, ·) :M nε → Rn is continuously differentiable in a neighborhood of~x0. Then, given an
Initial Value Problem IVP for an n-dimensional system of ODEs
d~x(t)
dt
= ~F (t,~x(t)) , ~x(0) = ~x0 ∈ Rn , (4.13)
20
has a unique solution. See Theorem 6.4 [4] or [1]. The corresponding Euler method, for
small ∆t > 0, takes the form
∆~xk
∆t
= ~F(tk,~xk) , or

tk+1 = tk + ∆t
~xk+1 = ~xk + ~F(tk,~xk)∆t
, (4.14)
where ∆~xk ≡~xk+1−~xk. It is well known that as ∆t → 0 the method becomes increasingly
accurate, and converges to the solution of (4.13) onN n+1ε . However, in practice, the round-
off errors accumulate and the computation time increases. See [13]. A comparison is made
using a higher order method, and the results are given in the appendix.
4.4 Runge-Kutta Method for solving ODEs
There are various orders of Runge-Kutta methods that can be used to numerically inte-
grate the system in (4.13). The popularity of this approach is because it does not require
differentiating ~F , unlike the higher-order Taylor methods [10]. The second order method
used here, referred to as RK2, involves a step-by-step process that provides an approxima-
tion for~xi+1, as with the Euler method, but uses mid-point information, giving
tk+1 = tk + ∆t
~xk+1 = ~xk + ~F
(
tk +∆t/2, ~xk +~F(tk,~xk)∆t/2
)
∆t
. (4.15)
A comparison between Euler’s method and RK2 is given in the appendix. In the special
case that ~F(t,~x) = M~x, for a constant coefficient n×n matrix M, then
~xk+1 = ~xk + ∆t M ·~xk + (∆t2/2)M2 ·~xk ,
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which contains three terms in the Taylor expansion of eM∆t , as shown in (4.3). This explains
why RK2 is a second-order method in ∆t.
4.5 Numerical solution for a deterministic model of chemotherapy
Time, t ∈ [0,100], is the only independent variable. The number of cancer cells of dif-
ferent types, I∗, is the main dependent variable. A cell-type may be susceptible or sensitive
to a drug, or may be resistant or immune to a drug. An application of a treatment cock-
tail, represented by a rate vector ~κ, is expected to cause many initial cancer-cell deaths.
However, another possible process can occur, represented by rate vector ~τ, where some
susceptible cancer cells transform into drug resistant cells. A simple form of the system of
ordinary differential equations ODEs is
d~I
dt
= −diag(~κ)~I + ~τ . (4.16)
If~τ linearly depends on~I and is independent of t, then a unique solution is easy to find. In
this case,~τ= T ·~I for a square matrix T . A weakness of this model is that it always predicts
the survival of some cancer cells. Therefore, no treatment could ever be successful.
Here 0 = s ≡ susceptible and 1 = r ≡ resistant. Writing equation (4.15) as a matrix
system, one has
d~I
dt
= −K ·~I + T ·~I ,
where the 4×4 evolution matrices are
K =
κ0 0 0 00 κ1 0 00 0 κ2 0
0 0 0 0
 , T =

−τ 01 − τ 02 0 0 0
τ 01 −τ 13 0 0
τ 02 0 −τ 23 0
0 τ 13 τ
2
3 0
 .
Note that setting κ3 = 0 models the loss of effectiveness of the treatment for the I3-type
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cells (cancer cells resistance to both drugs). As is required for a transition or stochastic
matrix, the sum of each column in T vanishes. Also, the T matrix is lower triangular,
which indicates that a resistant cell cannot become susceptible. The total number of cells
is given by
N(t) ≡ I0(t) + I1(t) + I2(t) + I3(t) , (4.17)
which decreases over time, but approaches a constant asymptote.
N(t)
I0(t)
I3(t)
I1, I2
Figure 2: Numerical solutions for deterministic model (I0, I1, I2, I3, N).
We solve equation (4.15) numerically for a two-drug cocktail starting with initial con-
ditions:
I0(0) = 100 , I1(0) = I2(0) = I3(0) = 0 . (4.18)
The decay rate parameters are set to
κ0 = 0.02 , κ1 = 0.03 , κ2 = 0.04 . (4.19)
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and the transition rates are set to
τ01 = 0.03 , τ
0
2 = 0.04 , τ
1
3 = 0.05 , τ
2
3 = 0.06 . (4.20)
Parameters are chosen so that the treatment time is short compared with the cancer-cell
growth rate. The conclusion is that half of the cells survive, thus no remission is possible.
Remark 4.4. The square matrix M =−K+T has the properties:
• The diagonal elements are non-positive;
• The matrix is lower triangular.
These ensure that the eigenvalues are non-positive, and thus the system does not grow
exponentially.
CHAPTER 5: Two-Drug Cocktail as a Treatment Strategy
When a series of drugs are administered, the actual microscopic responses of the suscep-
tible cancer cells are very difficult to model. In practice, one is really just interested in the
effectiveness of the treatment. To understand the process, we consider increasing levels of
complexity. This will help to establish notation and definitions.
5.1 Two-Drug Treatment, One-Cell System
Consider a chemotherapy involving two drugs. A cancer cell can be in one of four states
during a treatment, if it has not yet died, expressed as:
~s0 ≡
(
0
0
)
=
(
s
s
)
, ~s1 ≡
(
0
1
)
=
(
s
r
)
, ~s2 ≡
(
1
0
)
=
(
r
s
)
, ~s3 ≡
(
1
1
)
=
(
r
r
)
. (5.1)
Here 0 = s ≡ susceptible and 1 = r ≡ resistant. It is assumed that a cell transforms or
dies discretely, meaning that there is some non-zero time between changes of state. An
unknown in this process is the time between different states, and this is what has to be
modeled in the stochastic approach. Paths involving no cancer deaths is given in Figure 3.
Figure 3a First change of state; 3b Second change; 3c Combined changes.
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Consider a single cancer cell being treated with a cocktail of two drugs for t ≥ 0. The
probability that it is in a susceptible state at time t is denoted pi〈0〉(t), and this probability
changes according to the equation
pi′〈0〉(t) = −κ0,1 ·pi〈0〉(t) − κ0,2 ·pi〈0〉(t) (5.2)
− τ01 ·pi〈0〉(t) − τ02 ·pi〈0〉(t) .
The death rate will be combined into a single constant κ0 ≡ κ0,1 +κ0,2. The model in
(5.2) suggests that the single cell will not remain susceptible and so must decay into one of
the other states if it does not die. Becoming susceptible to drug 1 is modeled by
pi′〈1〉(t) = − κ1,3 ·pi〈1〉(t) (5.3)
+ τ01 ·pi〈0〉(t) − τ13 ·pi〈1〉(t) .
Similarly, for drug 2 one obtains the equation
pi′〈2〉(t) = − κ2,3 ·pi〈2〉(t) (5.4)
+ τ02 ·pi〈0〉(t) − τ23 ·pi〈2〉(t) .
The final differential equation is for the probability of resistance to both drugs,
pi′〈3〉(t) = + τ
1
3 ·pi〈1〉(t) + τ23 ·pi〈2〉(t) . (5.5)
There remains to consider the desired state of the system, which is the situation where there
is no cancer cell. The probability of this at time t is denoted pi /0(t) and satisfies
1 = pi〈0〉(t) + pi〈1〉(t) + pi〈2〉(t) + pi〈3〉(t) + pi /0(t) . (5.6)
Taking the derivative of both sides, rearranging, and using equations (5.2)-(5.5)gives:
pi′/0(t) = κ0,1 ·pi〈0〉(t) + κ1,3 ·pi〈1〉(t) + κ2,3 ·pi〈2〉(t) . (5.7)
We can now combine these equations into a 5-dimensional system of ODEs
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d
dt

pi〈0〉
pi〈1〉
pi〈2〉
pi〈3〉
pi /0
 =

−κ0− τ01− τ02 0 0 0 0
τ01 −κ1,3− τ13 0 0 0
τ02 0 −κ2,3− τ23 0 0
0 τ13 τ
2
3 0 0
κ0 κ1,3 κ2,3 0 0
 ·

pi〈0〉
pi〈1〉
pi〈2〉
pi〈3〉
pi /0
 . (5.8)
Remark 5.1. The generator of (5.8) has the properties that:
• The diagonal elements are non-positive;
• The off-diagonal elements are non-negative;
• The sum of each columns is zero.
The consequence is that the sum of the probability five-component vector
~pi(t) ≡ (pi〈0〉 pi〈1〉 pi〈2〉 pi〈3〉 pi /0)T (5.9)
is a constant. Using the initial condition
~pi(0) ≡ (1 0 0 0 0)T , (5.10)
we see that #(~pi(t)) = #(~pi(0)) = 1 for all t ≥ 0.
Theorem 5.2. Let M be a constant coefficient square matrix, whose columns add to 0.
Then the linear ODE:~y′ =M~y, with~y(0) =~y0 ∈R, has a solution~y(t) where the sum of its
components are constant.
Proof. First note that #(~y) =~1T ·~y. Thus, applying~1T to the left of the ODE gives,
#~y(t)′ =
(
~1T ·~y
)′
= ~1T ·~y′ = ~1T ·M ·~y =
(
MT ·~1
)T ·~y = ~0 ·~y = 0 .
Here we used that~1T ·M =~0, meaning that the sum of the columns of M vanishes.
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A plot of the numerical solution to the IVP in (5.9) with Initial Condition (5.9) is identi-
cal with that of Figure 2 except that pi /0(t) = 1−N/100. The corresponding PGF is simply
Ψ(t;x1,x2) = pi〈0〉 · x0 + pi〈1〉 · x1 + pi〈2〉 · x2 + pi〈3〉 · x3 + pi /0 .
Once constructed, the PGF can be used to derive the probabilities using partial derivatives
and substitution:
pi〈 j〉(t) =
∂Ψ(t;x1,x2)
∂x j
, pi /0(t) = Ψ(t;0,0) .
The goal of any treatment is to make limt→∞Ψ(t,0,0) as close to 1 as possible.
5.2 Two-Drug Treatment for a Two-Cell System
When there is more than one cancer cell in the system, our perspective must change
from the deterministic perspective. Suppose a 2-drug treatment is begun at t = 0 and ends
at t = T . Each cell can be in one of four states 0, 1, 2 and 3, where
• 0: both cells are susceptible to both drugs,
• 1: one cell is resistant and one cell is susceptible,
• 2: one cell is resistant and one cell is susceptible,
• 3: both cells are resistant to both drugs.
The set of different states of the system are given by the following two methods{ 〈3,3〉= 20, 〈3,2〉= 19, 〈3,1〉= 18, 〈3,0〉= 17,
〈2,3〉= 16, 〈2,2〉= 15, 〈2,1〉= 14, 〈2,0〉= 13,
〈1,3〉= 12, 〈1,2〉= 11, 〈1,1〉= 10, 〈1,0〉= 9, (5.11)
〈0,3〉= 8, 〈0,2〉= 7, 〈0,1〉= 6, 〈0,0〉= 5,
〈3〉= 4, 〈2〉= 3, 〈1〉= 2, 〈0〉= 1, 〈〉= 0 } ,
which are found to be convenient for both the theoretical and numerical work. Counting
elements in this set identifies 21 different states. However, some states are considered
28
equivalent, or in the same class, since the order is not important. For example,
〈2,1〉= 14∼ 〈1,2〉= 11 .
By inspection of (5.11) the actual number of different states is found to be 15. At t = 0 the
system is in the
initial state ≡ 〈0,0〉= 5 ,
and as t→ ∞ the system will most likely be in either
resistant states → 〈3,3〉= 20 , or 〈3〉= 4 ,
or the most desirable situation
disease-free state ≡ 〈〉= 0 .
As in the one-cell case, we associate probabilities to the possible states of the system. Each
cell can be in one of four states 0, 1, 2 and 3, as discussed in the one-cell case. Now we
create a function
ι j → # cells of type j for j ∈ {0, 1, 2, 3}= Z4 .
In the 2-cell case the range of ι j is Z3 = {0, 1, 2}. The notation that will be employed is
for the probabilities is
piι0,ι1,ι2,ι3 so that 0≤ ι0+ ι1+ ι2+ ι3 ≤ 2 , 0≤ ι j ≤ 2 .
The condition for the ι j’s corresponds to the interior and boundary of a system in 4-
dimensions. The number of different equivalent classes of states are:
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4 (both cells of the same type) + (4 ·3/2) (both cells different) (5.12)
+ 4 (one cell types) + 1 (no cells) = 15 .
Remark 5.3. For example pi0,1,0,1(t) is the probability that the system has one cell of type
1 (resistant to drug 1) and another cell of type 3 (resistant to both drugs). Conversely
pi0,0,2,0(t) is the probability that both cells are of type 2 (resistant to drug 2).
The notation
~ι = (ι0, ι1, ι2, ι3) ,
will be used, along with variations, as needed. The initial probability distribution is
pi~ι(0) = 0 , for 0≤ ι0 ≤ 1 , and pi2,0,0,0(0) = 1 . (5.13)
By the end of the treatment period T one expects that pi2,0,0,0(T ) ' 0 meaning that any
surviving cancer cells will be resistant to at least one of the drugs. The expected outcome
is such that
pi0,0,0,2(T ) + pi0,0,0,1(T ) + pi~0(T ) ' 1 , pi~0(T ) ≡ pi0,0,0,0(T )  0 ,
Before computing the evolution of the probabilities, we construct the PGF as
Ψ(t;~x) = ∑
~ι 6=~0
pi~ι(t) ·∏
ι j∈~ι
xι jj + pi~0(t) . (5.14)
Referring to the notational mapping in (5.11), the term corresponding with pi0,1,0,1(t) = pi18
has the power x1 · x3. Conversely, probability function pi0,0,2,0(t) = pi15 has the power x22.
Combining these gives the expression for the PGF from (5.14)
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Ψ = pi20 · x23 + 2pi19 · x3 · x2 + 2pi18 · x3 · x1 + 2pi17 · x3 · x0 + pi15 · x22 (5.15)
+ 2pi14 · x2 · x1 + 2pi13 · x2 · x0 + pi10 · x21 + 2pi9 · x1 · x0 + pi5 · x20 +
+ pi4 · x3 + pi3 · x2 + pi2 · x1 + pi1 · x0 + pi0 .
This demonstrates the complexity of the PGF in the simplest non-trivial case of 2-drugs
and 2-cells. In this expression only the probabilities pi j depend on t explicitly, so we can
take the partial of Ψ with respect to t to obtain the differential equation
∂Ψ(t;~x)
∂t
= ∑
~ι 6=~0
pi ′~ι (t) ·∏
ι j∈~ι
xι jj + pi
′
~0
(t) . (5.16)
Then we use the Kolmogorov Forward Equations to replace the functions pi′j(t) with just
pi j(t). Once this is done we can make (5.16) into a PDE for Ψ. The entire expression will
not be written out, but let us consider the first two terms.
pi′20 · x23 =
(−τ23(2pi19)− τ13(2pi18))x23 = −x3∂x2 τ23 ·pi19 · x3x2 − x3∂x1τ13 ·pi18 · x3x1 .
Thus (5.16) can be expressed as
∂tΨ ≡ ∂Ψ(t;~x)∂t = LΨ(t;~x) = ∑v j(~x)
∂Ψ(t;~x)
∂x j
= ~v ·∇Ψ , (5.17)
where L is a first-order linear partial differential operator PDO with variable coefficients
v j(~x) that are independent of t. The initial probabilities are stated in (5.13). Substituting
these into (5.15) gives the Initial Conditions for the PDE in (5.17) to be
Ψ(0,~x) = x23 . (5.18)
Note that all the probabilities vanish except for pi20(0) = 1. Thus, to solve the IVP as
31
defined by (5.17) and (5.18) we employ the method of characteristics, and assume that
~x =~x(t). Then we can rewrite (5.17) as
dΨ
dt
= ~v ·∇Ψ = 0∂Ψ
∂t
− ~v ·∇Ψ = 0 . (5.19)
The immediate solution to (5.19) is that Ψ = constant, as a function of t. Thus along a
characteristic γ the PGF satisfies Ψ|γ = x23. Characteristic curves are found by solving the
system of ODEs: ~x′ =~v(~x) using different Initial Conditions IC. The IC that x3(0) = 1 and
0 = x2(0) = x1(0) = x0(0) gives the probability of resistance over time. Since we are most
interested in the value of pi~0(T ), the probability of the treatment being successful, we need
to use the IC that x3(0) = x2(0) = x1(0) = x0(0) = 0.
5.2.1 Pathways for the Two Cell - Two Drug Example
The One Cell - Two Drug case reduces to the deterministic situation. The case of two
cancer cells becomes more complicated, involving 21 different states. For example, both
cells susceptible to both drugs, one cell susceptible to both but the other now resistant, one
cell extinguished but the other resistant to both drugs, etc. The Kolmogorov Forward (dif-
ferential) equation gives a system for the evolution of the probabilities. A sample equation
is
pi′0,1,0,1(t) = −κpi0,1,0,1 − τ1pi0,0,0,2 + τ2pi1,0,0,1 + τ2pi0,1,1,0 . (5.20)
The quantity pi0,1,0,1 is the probability that one cell is resistant to drug 1, and the other
cell is resistant to both. It decreases if a cell dies, at rate κ > 0 due to the chemotherapy
(good), and it decreases at a rate τ1 > 0 due to mutations (bad). The probability will grow
only due to transitions from other states at the rates τ2 and τ3. Solving the system, starting
with pi~I(0) = 0 except pi~0(0) = 1, gives solutions similar to deterministic model, but the
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interpretation is different.
Figure 4 Schematic of various actual pathways.
Using a stochastic process allows us to compute the probability of having no cancer
cells, within a time period [0,T ]. This leads to a much more realistic model for the treatment
of cancer using a cocktail of drugs. One obvious outcome of the model is that the objective
of cancer-drug researchers to make κ large and τ small.
5.2.2 Solution to the Stochastic Differential Equations
There are three sets of equations to solve. The first are the PDEs for the probabilities
pi~I(t). The second is the equation
dΨ
dt
= 0, and this implies that the initial form of Ψ= xN0~0
holds for all time. Thus, although the PGF Ψ is independent of time, its components vary.
They satisfy a system of ODEs
d~x
dt
= −~v .
Solving these gives two quantities that change with time, piI(t) and ~x(t). Using equation
(5.10), we construct the PGF. This allows us to compute the probability of having no cancer
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cells, within a time period [0,T ],
P(I~1 = 0) = Ψ(T,~I(T )) .
This leads to a more realistic model for the treatment of cancer using a cocktail of drugs.
The quantity pi0,1,0,1 is the probability that one cell is resistant to drug 1, and the other
cell is resistant to both. The probabilities with surviving cells decrease at rates κi > 0 due
to the chemotherapy (good), but can increase at a rate τ jk > 0 due to mutations (bad). The
solutions to the equations in (5.10) are probabilities of the different states. A sample is
p˙i0,1,0,1(t) = −κ1 ·pi0,1,0,1 − τ13 ·pi0,1,0,1 + τ01 ·pi1,0,0,1 + τ23 ·pi0,1,1,0 . (5.21)
The initial conditions are: pi0,0,0,0(0) = 1 , otherwise pi∗,∗,∗,∗ = 0 .
pi0,0,0,1
pi0,0,0,0
pi0,0,0,2
Figure 6. Numerical solutions pi∗(t) to the Kolmogorov Forward Equations.
Using the same parameters as in the deterministic case, there are three dominant possi-
ble outcomes, based on the probability distributions:
1) pi0,0,0,1(100) ' 49.7% (treatment partially successful).
2) pi0,0,0,0(100) ' 27.9% (remission achieved);
3) pi0,0,0,2(100) ' 22.2% (treatment unsuccessful);
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The total is nearly 100% indicating that further use of the treatment will have little effect.
5.3 Product of Probabilities Approach
The stochastic differential equation approach just studied can be modified to consider
cross interactions [7]. However, if the cells are truly indistinguishable, then the one-cell
distributions, given in (5.9), can be combined giving the identity
1 =
(
pi〈0〉+pi〈1〉+pi〈2〉+pi〈3〉+pi /0
)2
. (5.22)
This has 25 separate terms. However the number of duplicates are (5 · 4/2) = 10. Thus
there are only 15 different states. By writing programs for each case using ∆t = 1 and
considering the values at t = 100 we can compare the difference between the two methods,
summarized below.
Table 1: Comparison between stochastic (KFE) approach, and product approach.
The agreement of the two approaches is due to the fact that evolution of each cancer
cell is considered to be independent in this thesis. However, this is not the case in-vivo,
so the stochastic differential equation approach would have the be modified. The theory is
now in place to consider more difficult, but realistic situations.
5.4 Higher-Order Stochastic Cases
We briefly consider the next order cases to demonstrate the increase in complexity asso-
ciated with stochastic modeling. Independence of cells will still be assumed here.
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5.4.1 2-drugs and N-cells
In the 2-drug case, there are 22+1 different states represented by the numbers (used as
indices) {0,1,2,3, /0 = 4} = Z5. When there are N different cancer cells, the system will
have 5N possible configurations. However, if these cells are considered to be independent,
then the number unique configurations decreases. We can understand this by first letting
ι j(t) denote the number of cells in state j ∈ Z5, at any time t. Then we can construct the
vector
~ι(t) = (ι0, ι1, ι2, ι3, ι4) ,
and impose the restrctions that
#(~ι) ≡ ι0+ ι1+ ι2+ ι3+ ι4 = N and 0≤ ι j ≤ N .
Now we have to choose 5 different whole numbers from N in such a way that the total is N.
To do this, consider a string of N+4 numbers where one chooses 4. The 4 choices breaks
the string of N numbers into 5 parts. The first part counts to ι0. The second to ι1, and so
on. This gives, [9]
Unique states for N cells in 2-drug environment =
(
N+4
4
)
. (5.23)
Example 5.4. The two-drugs and two-cells gives #(~ι) = 2 = N and the number of distinct
states are
(6
4
)
= 15, which was already determined in (5.12). The two-drug and three-cell
case has #(~ι) = 3 which results in the number of distinguishable states to be
4 (three cells of the same type) + (4×3) (two the same, one different)
+ (4×3×2/3!) (all three different)
10 (two cells) + 4 (one cell) + 1 (no cells) = 35 .
However, from (5.23) one quickly obtains
(7
4
)
= 35 distinct states.
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5.4.2 m-drugs and N-cells
Finally, when there are m drugs used, then there are 2m−1 ways to be resistant to at least
one of the drugs. Otherwise, there is the state of susceptibility to all drugs, and the state of
no cells. This gives a total of 2m+1 states. We can index the single cell states as
Unique states for N-cells in m-drug environment =
(
N+2m
2m
)
. (5.24)
Thus, in the special case of 3-drugs and 2 cells there are
(2+23
23
)
=
(10
8
)
= 45 cases.
CHAPTER 6: Conclusions
In many systems, a deterministic approach is sufficient to understand future behavior.
However, for complex systems with many pathways, a stochastic approach leads to more
realistic estimates of outcomes. In particular, this approach to modeling the progress of
treatments allows for meaningful results, like the probability of achieving remission. Re-
search into the stochastic method of predicting outcomes gives a way to analyze the drug-
effectiveness parameters that can be measured and adjusted for optimality. As the use of
multiple drugs during a single treatment becomes the norm, these methods will need to be
further refined.
CHAPTER 7: APPENDIX I
Comparison between Euler Method and RK2 It was observed that there is not a significant
difference between Euler’s method and Runge-Kutta of order 2. The programs were written
in EXCEL. We only show the results for N(t).
Figure 7. Numerical solutions using Euler and RK2 methods.
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Figure 8. Differences for the Euler and RK2 numerical methods.
CHAPTER A: APPENDIX II
The following were programmed in EXCEL and used to produce Figure 6:
Pi 2000 = B2+(-2*S3*B2-2*V 3*B2-2*X3*B2)*Z3
Pi 1100 = C2+(2*V 3*B2-(V 3+X3+W3)*C2-(S3+T 3)*C2)*Z3
Pi 1010 = D2+(2*X3*B2-(S3+U3)*D2-(V 3+X3+Y 3)*D2)*Z3
Pi 0110 = E2+(X3*C2+V 3*D2-(W3+Y 3)*E2-(T 3+U3)*E2)*Z3
Pi 0200 = F2+(V 3*C2-2*(T 3+W3)*F2)*Z3
Pi 0020 = G2+(X3*D2-2*Y 3*G2-2*U3*G2)*Z3
Pi 1001 = H2+(W3*C2+Y 3*D2-S3*H2-(V 3+X3)*H2)*Z3
Pi 0011 = I2+(W3*E2+2*Y 3*G2+X3*H2-U3*I2-Y 3*I2)*Z3
Pi 0101 = J2+(Y 3*E2+2*W3*F2+V 3*H2-T 3*J2-W3*J2)*Z3
Pi 0002 = K2+(W3*J2+Y 3*I2)*Z3
Pi 1000 = L2+(S3*(2*B2-L2)+T 3*C2+U3*D2-(V 3+X3)*L2)*Z3
Pi 0100 = M2+(S3*C2+2*T 3*F2+U3*E2+V 3*L2-W3*M2-T 3*M2)*Z3
Pi 0010 = N2+(S3*D2+T 3*E2+2*U3*G2+X3*L2-Y 3*N2-U3*N2)*Z3
Pi 0001 = O2+(S3*H2+T 3*J2+U3*I2+W3*M2+Y 3*N2)*Z3
Pi 0000 = P2+(S3*L2+T 3*M2+U3*N2)*Z3
Total = B3+C3+D3+E3+F3+G3+H3+I3+J3+K3+L3+M3+N3+O3+P3
Decay — Transition Params —- Delta t
k0 k1 k2 — t01 t13 t02 t23
0.02 0.03 0.04 — 0.03 0.04 0.05 0.06 — 1
pi 0002 pi 0001 pi 0000 — Total
0.221708 0.497365 0.27894 — 0.998013
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